openPR Logo
Press release

Glioblastoma Multiforme Market Segmentation Trends and Industry Growth Forecast (2024-2031) - Pfizer, Genentech, Amgen.

10-16-2024 02:51 PM CET | Health & Medicine

Press release from: DataM Intelligence 4market Research LLP

Glioblastoma Multiforme Market

Glioblastoma Multiforme Market

DataM Intelligence has released a new research report on the Glioblastoma Multiforme market. The report provides a detailed analysis of current and emerging trends, offering insights into the market dynamics. It utilizes Porter's Five Forces model to assess key factors such as supplier and customer relationships, risks from various agents, competitive intensity, and opportunities for new entrants. The study also includes research data from various companies, analyzing factors like benefits, gross margins, and strategic decisions in the global market. The report is enriched with tables, charts, and infographics for a clear presentation of the findings.

The Global Glioblastoma Multiforme Market reached USD 2.4 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 4.5 billion by 2031. The global glioblastoma multiforme market is expected to exhibit a CAGR of 8.6% during the forecast period 2024-2031.

Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/glioblastoma-multiforme-market

Glioblastoma multiforme (GBM) is an aggressive and highly malignant type of brain tumor that arises from glial cells, specifically astrocytes. It is characterized by rapid growth, invasive behavior, and a tendency to recur despite treatment. GBM typically presents with symptoms such as headaches, seizures, cognitive changes, and neurological deficits, depending on its location in the brain. It is classified as a grade IV tumor according to the World Health Organization, indicating its high level of malignancy. Standard treatment options for GBM include surgery, radiation therapy, and chemotherapy, often combined to maximize efficacy. Unfortunately, the prognosis for GBM is generally poor, with a median survival rate of about 15 months, highlighting the need for ongoing research into more effective therapies and management strategies.

List of the Key Players in the Glioblastoma Multiforme Market:

Pfizer, Genentech, Amgen, Merck & Co., Inc., Teva Pharmaceutical Industries, Ltd., Arbor Pharmaceuticals LLC., Sun Pharmaceutical Industries, Ltd., F. Hoffmann-Le Roche AG, Amneal Pharmaceuticals and Karyopharm Therapeutics, Inc.

Key Developments:

On June 3, 2023, Chimeric Therapeutics announced the initiation of a new Phase IB clinical trial for CHM 1101 (CLXT CAR T) cell therapy aimed at treating individuals with recurrent or progressive glioblastoma multiforme (GBM). The trial will assess the safety and efficacy of CHM 1101 in patients diagnosed with this highly aggressive form of primary brain cancer.

Research Process:

Both primary and secondary data sources have been used in the global Glioblastoma Multiforme Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Segment Covered in the Glioblastoma Multiforme Market:

By Treatment type: Drugs (Temozolomide, Bevacizumab, Carmustine, Others), Immunotherapy, Electric field therapy, Others.

By Type of molecule: Small molecules, Biologics.

By Route of administration: Oral, Parenteral.

By End-user: Hospitals, Clinics, Others.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/glioblastoma-multiforme-market

Regional Analysis:

➣ North America (US, Canada, Mexico)

➣ Europe (Germany, Russia, UK, France, Italy, Spain, Rest of Europe)

➣ Asia-Pacific (China, India, Japan, Australia, Rest of Asia Pacific)

➣ South America (Brazil, Argentina, Rest of South America)

➣ Middle East and Africa

**The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted**

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Glioblastoma Multiforme market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Glioblastoma Multiforme Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Glioblastoma Multiforme market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Glioblastoma Multiforme Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Have any Query? Talk to our Expert @ https://www.datamintelligence.com/enquiry/glioblastoma-multiforme-market

The Research Report Offers Answers To The Following Questions:

☛ What is the expected growth rate of the global market for the forecast period?

☛ What are the key driving factors that are responsible to shape the fate of the Glioblastoma Multiforme market during the forecast period?

☛ What will be the overall size of the market during the analysis period?

☛ What are the prominent market trends which influence the development of the Glioblastoma Multiforme market across various regions?

☛ Who are the key market players and the market strategies that have helped them to secure the leading position in the global market?

☛ What are the challenges and threats that are likely to act as a barrier to the growth of the Glioblastoma Multiforme market?

☛ What are the major opportunities that the companies can get to attain success in the world?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Glioblastoma Multiforme Market Segmentation Trends and Industry Growth Forecast (2024-2031) - Pfizer, Genentech, Amgen. here

News-ID: 3696268 • Views:

More Releases from DataM Intelligence 4market Research LLP

United States Tapentadol Market Surges at 6.8% CAGR - $1.2 Billion Milestone by 2031, Led by Janssen Pharmaceuticals and Grünenthal as Top Competitors | DataM Intelligence
United States Tapentadol Market Surges at 6.8% CAGR - $1.2 Billion Milestone by …
Leander, Texas and TOKYO, Japan - Dec. 02, 2025. According to DataM Intelligence, the United States Tapentadol Market Size is growing from USD 750 million in 2023 to USD 1.2 billion by 2031, registering a robust CAGR of 6.8% during 2024-2031. The surging demand for opioid alternatives, the expansion of chronic pain therapies, and advancements in extended-release formulations are fueling the need for enhanced tapentadol solutions that maximise analgesic efficacy
United States Horseradish Peroxidase Market Surges at 7.2% CAGR Led by Bio-Rad Laboratories and Thermo Fisher Scientific as Top Competitors | DataM Intelligence
United States Horseradish Peroxidase Market Surges at 7.2% CAGR Led by Bio-Rad L …
Leander, Texas and TOKYO, Japan - Dec. 02, 2025. According to DataM Intelligence, the United States Horseradish Peroxidase Market Size is growing from USD 22.5 million in 2023 to USD 39 million by 2031, registering a robust CAGR of 7.2% during 2024-2031. The surging demand for advanced diagnostic tools, the expansion of immunoassay kits, and breakthroughs in recombinant enzyme production are fueling the need for enhanced HRP formulations that maximise
Frozen Fruits Market Surges Toward US$6.54 Billion by 2030 - Asia-Pacific Leads with 43% Share as Organic, Plant-Based & IQF Trends Redefine Global Nutrition
Frozen Fruits Market Surges Toward US$6.54 Billion by 2030 - Asia-Pacific Leads …
According to DataM Intelligence, the global frozen fruits market size was valued at US$3,957.4 million in 2022 and is forecasted to reach US$6,549.4 million by 2030, growing at a CAGR of 6.5% from 2024 to 2031. This steady growth is propelled by rising health consciousness among consumers, increasing demand for convenient and nutritious food options, expanding food processing and service sectors, growing preference for organic and plant-based products, surging popularity
United States Feed Testing Market Booms on 6.50% CAGR - North America Dominates 35% Share Amid Rising FDA Compliance & Livestock Safety Demands
United States Feed Testing Market Booms on 6.50% CAGR - North America Dominates …
According to DataM Intelligence, the global feed testing market size was valued at US$3.50 billion in 2024 and is forecasted to reach US$5.70 billion by 2031, growing at a CAGR of 6.50% during the forecast period (2024-2031). This steady growth is propelled by stringent regulatory standards for animal feed safety, rising demand for high-quality meat and dairy products, increasing livestock production, growing pet food safety concerns, and expanding focus on

All 5 Releases


More Releases for Glioblastoma

Key Trends Shaping the Future Glioblastoma Multiforme Market From 2025-2034: Adv …
Which drivers are expected to have the greatest impact on the over the glioblastoma multiforme market's growth? The growing number of brain disorder cases is anticipated to boost the glioblastoma multiforme market in the coming years. A brain disorder is a condition that affects the brain's structure or function, leading to cognitive, emotional, or physical difficulties. The rise in brain disorder cases is attributed to factors such as an aging population,
Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Glioblastoma Pipeline Insight, 2024," report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Glioblastoma Pipeline Report * DelveInsight's Glioblastoma pipeline report depicts
Glioblastoma Multiforme Market Insights, Forecast to 2031
"Glioblastoma Multiforme Market 2024," The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Glioblastoma Multiforme market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Glioblastoma Multiforme industry, providing stakeholders with a nuanced perspective on market
Beyond Bravery - Bill Fitzpatrick's Fight Against Glioblastoma
Bill Fitzpatrick Jr, a retired sales professional from GE, has recently ventured into the world of writing with his debut book. Inspired by his experiences during taking care of his wife, who had Glioblastoma, Bill felt the need to share his journey and provide support to other families navigating similar challenges. In this article, we will dive into Bill's background, his motivation for becoming an author, details about his latest
Recurrent Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Recurrent Glioblastoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Recurrent Glioblastoma Pipeline Report DelveInsight's Recurrent Glioblastoma
Revolutionizing Glioblastoma Treatment Strategies: A Deep Dive into the Glioblas …
The Glioblastoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Glioblastoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Glioblastoma pipeline landscape and fostering the potential growth of Glioblastoma therapeutic advancements. Key Takeaways from the Glioblastoma Pipeline Report • DelveInsight's Glioblastoma pipeline report depicts a robust space with 195+ active players